Foscarbidopa/foslevodopa

Foscarbidopa/foslevodopa, vândut sub numele de marcă Vyalev, este un medicament combinat cu doză fixă utilizat pentru tratamentul bolii Parkinson. Este o combinație de promedicamente pentru levodopa și carbidopa care a fost dezvoltată de AbbVie.^[1]^[2]^[3]^[4]^[5]

Note

^ Rosebraugh, Matthew; Kym, Philip; Liu, Wei; Facheris, Maurizio; Benesh, Janet (9 aprilie 2019). „A Novel Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson's Disease (P3.8-037)”. Neurology. 92 (15 Supplement). doi:10.1212/WNL.92.15_supplement.P3.8-037.
^ Facheris, Maurizio; Criswell, Susan; Pavasia, Nirav; Pahwa, Rajesh; Locke, Charles; Robieson, Weining; Shprecher, David (14 aprilie 2020). „Safety and Tolerability During a 4-Week Continuous Subcutaneous Infusion of ABBV-951, a New Drug Formulation for the Treatment of Parkinson's Disease: Final Results of a Phase 1b Study (1384)”. Neurology. 94 (15 Supplement).
^ Facheris, Maurizio; Benesh, Janet; Streit, Janet; Robieson, Weining; Zadikoff, Cindy; Standaert, David (14 aprilie 2020). „Safety and Tolerability in Parkinson's Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study (4233)”. Neurology. 94 (15 Supplement).
^ Rosebraugh, Matthew; Kym, Philip; Liu, Wei; Facheris, Maurizio (14 aprilie 2020). „ABBV-951 Maintains Stable Levodopa Exposure following Subcutaneous Infusion in Parkinson's Disease Patients (543)”. Neurology. 94 (15 Supplement). doi:10.1212/WNL.94.15_supplement.543.
^ Facheris, Maurizio; Robieson, Weining; Fisseha, Nahome; Standaert, David (13 aprilie 2021). „Efficacy and Safety of Foslevodopa/Foscarbidopa Versus Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients: Design of a Phase 3, Randomized, Double-Blind, Double-Dummy, Active Controlled 12-Week Trial (2251)”. Neurology. 96 (15 Supplement). doi:10.1212/WNL.96.15_supplement.2251.

[1] Rosebraugh, Matthew; Kym, Philip; Liu, Wei; Facheris, Maurizio; Benesh, Janet (9 aprilie 2019). „A Novel Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson's Disease (P3.8-037)”. Neurology. 92 (15 Supplement). doi:10.1212/WNL.92.15_supplement.P3.8-037.

[2] Facheris, Maurizio; Criswell, Susan; Pavasia, Nirav; Pahwa, Rajesh; Locke, Charles; Robieson, Weining; Shprecher, David (14 aprilie 2020). „Safety and Tolerability During a 4-Week Continuous Subcutaneous Infusion of ABBV-951, a New Drug Formulation for the Treatment of Parkinson's Disease: Final Results of a Phase 1b Study (1384)”. Neurology. 94 (15 Supplement).

[3] Facheris, Maurizio; Benesh, Janet; Streit, Janet; Robieson, Weining; Zadikoff, Cindy; Standaert, David (14 aprilie 2020). „Safety and Tolerability in Parkinson's Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study (4233)”. Neurology. 94 (15 Supplement).

[4] Rosebraugh, Matthew; Kym, Philip; Liu, Wei; Facheris, Maurizio (14 aprilie 2020). „ABBV-951 Maintains Stable Levodopa Exposure following Subcutaneous Infusion in Parkinson's Disease Patients (543)”. Neurology. 94 (15 Supplement). doi:10.1212/WNL.94.15_supplement.543.

[5] Facheris, Maurizio; Robieson, Weining; Fisseha, Nahome; Standaert, David (13 aprilie 2021). „Efficacy and Safety of Foslevodopa/Foscarbidopa Versus Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients: Design of a Phase 3, Randomized, Double-Blind, Double-Dummy, Active Controlled 12-Week Trial (2251)”. Neurology. 96 (15 Supplement). doi:10.1212/WNL.96.15_supplement.2251.

[1]

[2]

[3]

[4]

[5]